Navigation Links
SeqWright's Partnership With Third Wave Contributes to FDA Success
Date:3/31/2008

HOUSTON, March 31 /PRNewswire/ -- SeqWright Inc. today congratulated Third Wave Technologies Inc., Madison, Wis., on the successful FDA clearance of its InPlex(TM) CF Molecular Test. CLIA-certified SeqWright is a leader in the field of contract genomics and provided the FDA-level genotyping that ultimately validated the InPlex(TM) CF test by demonstrating it had 99.96% overall agreement with DNA sequencing. The validation played a critical role in the test gaining FDA clearance. SeqWright was responsible for providing the sequence verification for 19 cystic fibrosis (CF) variants from numerous patient samples.

The success of SeqWright's collaboration with Third Wave builds on a relationship established in 2004, when the two companies began work on Third Wave's UGT1A1 Molecular Assay. SeqWright provided FDA-level sequencing to validate the UGT1A1 pharmacogenetic test, which is used to identify patients susceptible to adverse reaction from a specific colorectal cancer treatment. The assay gained FDA clearance in August 2005. SeqWright was selected for the sequencing-based validation of Third Wave's InPlex(TM) CF test after the exemplary work it performed with Third Wave's UGT1A1 Molecular Assay.

"We are grateful for the contributions SeqWright has made to Third Wave's two successful FDA submissions," said Kevin T. Conroy, president and chief executive of Third Wave.

SeqWright CEO, Fei Lu, M.D., said, "We are proud of the success of our past and present collaborations with Third Wave Technologies and we are excited to be involved in the validation of these important diagnostic tests."

About SeqWright:

SeqWright Incorporated is a world-class genomic services support organization based in Houston, TX with more than a decade of experience specializing in providing access to state of the art Molecular Biology and Genomic services in a highly regulated GLP/CLIA environment. For additional information about SeqWright and its services, please visit http://www.seqwright.com.

About Third Wave Technologies:

Third Wave develops and markets molecular diagnostic reagents for a variety of DNA and RNA analysis applications to meet the needs of our customers. The company offers a number of products based on its Invader(R) chemistry for clinical testing. Third Wave offers in vitro diagnostic kits, and analyte specific, general purpose, and research use only reagents for nucleic acid analysis. For more information about Third Wave and its products, please visit the company's website at http://www.twt.com.


'/>"/>
SOURCE SeqWright Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
2. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
3. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
4. B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership
5. NASN Joins Partnership to Fight Chronic Disease
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
8. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
9. Partnership to Fight Chronic Disease Announces Ideas for Change in Health Care
10. Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement
11. Anthem Blue Cross and Blue Shield Partnership Plan Wins Nevada Immunization Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... ... RANKED Health , a program to critically evaluate and rank health-focused applications ... the program is to provide independent, unbiased and accurate information to help accelerate ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... and CEO of EMED, today signed a multifaceted agreement which will allow for ... Northern Caribbean University Department of Natural and Applied Sciences, Allied Health and Nursing ...
(Date:4/30/2016)... ... , ... well is a challenge for all of us, but there are things we can do to ... “Research is showing more and more that there are simple, yet important steps that can ... age.” Top priorities Dr. Kohli’s recommends for her patients include;, , exercise ...
(Date:4/29/2016)... , ... April 30, 2016 , ... ... of patented products, announces the Pick Up Springboard, an automotive invention that improves ... Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO and Creative ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April 16th ... for Botox and lip injections, which she underwent in order to feel more at ... and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
(Date:4/28/2016)... , April 28, 2016 ... development of innovative peptide and gene-based immunotherapeutics and vaccines for ... will be presenting at the 3rd Annual Growth Capital ... 5 th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: